Two blood pressure targets compared
This prespecified analysis included 12,434 participants without probable dementia at baseline, recruited in China. All were at least 50 years old and had type 2 diabetes, elevated systolic blood pressure, and increased cardiovascular risk. Their mean age was 63.7 years.
Participants were randomly assigned to intensive treatment targeting systolic blood pressure below 120 mmHg or standard treatment targeting below 140 mmHg. After one year, mean values were 121.6 and 133.2 mmHg, respectively: the assigned targets must therefore be distinguished from the values actually achieved.
Cognitive assessments were conducted annually and at the end of the study. Outcome assessors were unaware of group assignments, but treatment was open-label.
No statistically demonstrated cognitive difference
Over a median follow-up of 3.8 years, dementia or mild cognitive impairment was observed in 747 participants in the intensive group, compared with 783 in the standard group. Rates were 3.69 and 3.89 events per 100 person-years, respectively.
The hazard ratio was 0.96, with a 95% confidence interval of 0.86 to 1.06. These results therefore do not demonstrate a cognitive benefit from intensive treatment over this period. Nor do they prove that the two strategies are strictly equivalent.
An MRI signal, not proof of cognitive protection
In the MRI subgroup, white matter lesion volume increased less with intensive treatment. But this imaging measure cannot be equated with a reduction in dementia or an improvement in cognitive abilities.
This part of the study was also more limited: 862 participants had a baseline MRI and 605 had a final MRI. The imaging result and the main clinical result must therefore be considered separately.
What this analysis tells us
For this population, targeting lower blood pressure provided no demonstrated cognitive benefit over approximately four years. This analysis does not settle the question of longer-term effects or effects in people without diabetes.
The supplied abstract does not detail adverse effects or cardiovascular outcomes. On its own, it therefore cannot guide the choice between the two treatment strategies.
Limitations to keep in mind
Only the PubMed abstract was consulted, not the full text. The analysis covers a Chinese population with type 2 diabetes and increased cardiovascular risk, followed for a median of 3.8 years. The MRI subgroup is limited, and not all baseline MRIs were repeated. Adverse effects, funding, and conflicts of interest could not be verified from the dossier.
What we can take away
In BPROAD, improvement in a brain MRI marker was not accompanied by a demonstrated reduction in dementia or mild cognitive impairment.
Sources and provenance
- Effect of intensive blood pressure control on cognitive outcomes and brain structures in adults with type 2 diabetes: prespecified analysis of secondary outcomes of BPROAD randomised controlled trial.
Source date: 2026-11-12.
Journal Article, Randomized Controlled Trial, Multicenter Study · Résumé PubMed uniquement, texte intégral non consulté


